Are Investors Starting to Appreciate Array BioPharma's Belt Tightening? Print E-mail
By Staff and Wire Reports   
Wednesday, 29 June 2011 07:02
Panny StocksShares of Array BioPharma (Nasdaq:ARRY), the biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs appear to be bouncing off the bottom, for both technical and fundamental reasons.

As we look at the chart below, we see that the indicators and latest candlestick formation appear to be bullish, but it also helps that there has been some insider buying from CEO Robert Conway in recent days. Insider trading often occurs when employees or management believe that the public is not valuing their stocks properly. Because insider transactions are public information, knowing that insiders are purchasing stock can signal future stock appreciation.

Yesterday's trading action saw shares rise 4.55% to $2.30 +0.10 on very bullish action. In the past 52 weeks, shares of Array Biopharma have traded between a low of $2.06 and a high of $3.60 and just two weeks ago (June 17th) were at $2.06, which marked 57% of that high price.

Array BioPharma's proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease and includes several small molecule drug candidates that are designed to regulate targets in therapeutically important biologic pathways. Its discovery platform includes: structural biology, predictive informatics, high throughput screening, cell biology, lead generation, lead optimization, drug metabolism, pharmacology, process research & cGMP and clinical or regulatory technologies. 

Earlier in the month, Array announced that  it was reducing staff by another 20 percent, or 70 positions, as part of a “restructuring to extend its financial resources.”  In recent months, the drug research company has been cutting payroll and R&D costs as it has narrowed its research focus mainly to experimental drugs for which it has licensing deals.

As we look at the BioMedReports Trade Catalyst Calendar, we see that ARRY has three milestones listed this year. One Pahse Ib trial result for ARRY543 with Docetaxel (Advanced Solid Tumors), Another Phase Ib trial result, this time for ARRY543 with Gemzar for the treatment of Solid Tumors and finally a Phase I trial end status update for ARRY 403 for the treatment of Type II Diabetes. These events were discussed in previous press releases all issued by the company, and have no specific dates within 2011 specified.


Date Product Name Status Treatment Indication
    2011 ARRY543 with Docetaxel I Advanced Solid Tumors Phase Ib trial result
    2011 ARRY543 with Gemzar II Solid Tumors Phase Ib trial result
    2011 ARRY403 I Type II Diabetes Phase I trial end

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus